Modality
mAb
MOA
JAK1i
Target
TIM-3
Pathway
Apoptosis
PompeIPFAlzheimer's
Development Pipeline
Preclinical
Oct 2019
→ Aug 2028
PreclinicalCurrent
NCT03080225
2,933 pts·Alzheimer's
2025-12→2028-06·Terminated
NCT06631136
1,786 pts·IPF
2019-10→2028-08·Completed
4,719 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-06-202.2y awayInterim· Alzheimer's
2028-08-082.4y awayInterim· IPF
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Complet…
Preclinical
Termina…
Catalysts
Interim
2028-06-20 · 2.2y away
Alzheimer's
Interim
2028-08-08 · 2.4y away
IPF
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03080225 | Preclinical | Alzheimer's | Terminated | 2933 | 6MWD |
| NCT06631136 | Preclinical | IPF | Completed | 1786 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 |